These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27521112)

  • 21. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
    Bridgeman MB; Shah M; Foote E
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.
    Beccari MV; Meaney CJ
    Core Evid; 2017; 12():11-24. PubMed ID: 28356904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.
    Coppens R; Yang J; Ghosh S; Gill J; Chambers C; Easaw JC
    J Oncol Pharm Pract; 2019 Sep; 25(6):1366-1373. PubMed ID: 30124122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potassium: friend or foe?
    Rodan AR
    Pediatr Nephrol; 2017 Jul; 32(7):1109-1121. PubMed ID: 27194424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
    Dong L; Xu W; Deng Y; Tan J; Qin W
    Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patiromer: A Review in Hyperkalaemia.
    Kim ES; Deeks ED
    Clin Drug Investig; 2016 Aug; 36(8):687-94. PubMed ID: 27380495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patiromer: A Review in Hyperkalaemia.
    Blair HA
    Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patiromer: a significant advance in the management of hyperkalemia.
    Paton DM
    Drugs Today (Barc); 2015 Dec; 51(12):695-703. PubMed ID: 26798850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management.
    McCullough PA; Beaver TM; Bennett-Guerrero E; Emmett M; Fonarow GC; Goyal A; Herzog CA; Kosiborod M; Palmer BF
    Rev Cardiovasc Med; 2014; 15(1):11-23. PubMed ID: 24762462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
    Zannad F; Rossignol P; Stough WG; Epstein M; Alonso Garcia Mde L; Bakris GL; Butler J; Kosiborod M; Berman L; Mebazaa A; Rasmussen HS; Ruilope LM; Stockbridge N; Thompson A; Wittes J; Pitt B
    Int J Cardiol; 2016 Aug; 216():46-51. PubMed ID: 27140336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective.
    Fischer B; Serra A; Telser H
    Adv Ther; 2022 Jun; 39(6):2717-2730. PubMed ID: 35416597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of plasma aldosterone by glucose-induced paradoxical hyperkalemia in the presence of suppressed renin-angiotensin system.
    Radó JP
    Endokrinologie; 1978 Apr; 72(1):51-6. PubMed ID: 688983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin-Angiotensin-Aldosterone Blocking Agents.
    Borghi C; Ferri C; Pontremoli R; Sechi L; Grassi G
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):555-559. PubMed ID: 34709583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.
    Davidson JP; King AJ; Kumaraswamy P; Caldwell JS; Korner P; Blanks RC; Jacobs JW
    J Cardiovasc Pharmacol Ther; 2018 May; 23(3):244-253. PubMed ID: 29130735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    J Am Soc Hypertens; 2017 Dec; 11(12):783-800. PubMed ID: 29030153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
    Epstein M; Pitt B
    Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS; Bhagat AA; Anker SD; Butler J
    Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.